.

Deeper Knowledge, Faster

  • Find suppliers and generic API sources
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Farmers Insurance
Accenture
Express Scripts
Argus Health
UBS
Colorcon
Chubb
AstraZeneca
Federal Trade Commission
Merck

Generated: June 27, 2017

DrugPatentWatch Database Preview

Details for Patent: 9,132,239

« Back to Dashboard

Which drugs does patent 9,132,239 protect, and when does it expire?


Patent 9,132,239 protects RYZODEG 70/30, TRESIBA, SAXENDA, LEVEMIR FLEXTOUCH, NORDITROPIN FLEXPRO, XULTOPHY 100/3.6, and NOVOLOG FLEXTOUCH, and is included in seven NDAs.

This patent has eleven patent family members in ten countries.

Summary for Patent: 9,132,239

Title:Dial-down mechanism for wind-up pen
Abstract: The present invention relates to a dial-down mechanism for an injection device comprising a torsion spring for assisting injection of a dose of medicament from the injection device, the dial-down mechanism comprising a ratchet arm (21) engaging a ring element (10) and a reset element (30) which acts on a knob located on the periphery of the ratchet arm (21) to move the ratchet arm (21) out of engagement with the ring element (10) in order to allow the set dose to be reduced.
Inventor(s): Moller; Claus Schmidt (Fredensborg, DK), Markussen; Tom Hede (Bagsv.ae butted.rd, DK), Radmer; Bo (Hillerod, DK), Enggaard; Christian Peter (Vejby, DK)
Assignee: Novo Nordisk A/S (Bagsvaerd, DK)
Application Number:13/124,995
Patent Claim Types:
see list of patent claims
Use; Device;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Novo Nordisk Inc
RYZODEG 70/30
insulin aspart; insulin degludec
SOLUTION;SUBCUTANEOUS203313-001Sep 25, 2015RXYesYes9,132,239► SubscribeY
Novo Nordisk Inc
TRESIBA
insulin degludec
SOLUTION;SUBCUTANEOUS203314-001Sep 25, 2015RXYesNo9,132,239► SubscribeY
Novo Nordisk Inc
TRESIBA
insulin degludec
SOLUTION;SUBCUTANEOUS203314-002Sep 25, 2015RXYesYes9,132,239► SubscribeY
Novo Nordisk Inc
SAXENDA
liraglutide recombinant
SOLUTION;SUBCUTANEOUS206321-001Dec 23, 2014RXYesYes9,132,239► SubscribeY
Novo Nordisk Inc
LEVEMIR FLEXTOUCH
insulin detemir recombinant
INJECTABLE;SUBCUTANEOUS021536-005Oct 31, 2013RXYesYes9,132,239► SubscribeY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 9,132,239

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
08167547Oct 24, 2008
PCT Information
PCT FiledOctober 21, 2009PCT Application Number:PCT/EP2009/063801
PCT Publication Date:April 29, 2010PCT Publication Number: WO2010/046394

International Patent Family for Patent: 9,132,239

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia2009306387► Subscribe
BrazilPI0919925► Subscribe
Canada2738877► Subscribe
China102196835► Subscribe
Denmark2373361► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Cantor Fitzgerald
Daiichi Sankyo
Covington
Healthtrust
Novartis
Accenture
Fuji
Teva
AstraZeneca
UBS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot